An interventional study of transcranial focused ultrasound (tFUS) in Healthy and Olfaction, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Anosmia with a site in United States — 17 open to participants now, 20 under way, 1 of them phase 3. Anosmia · United States.
Among the 59 studies in Anosmia with a site in United States, this one is the 34th largest by planned enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2026, is one of 19 with no phase, reaches primary completion later than 11 of the 19 other live ones, and was the 56th registered.
180 studies on the registry are indexed under Anosmia; 45 are open to participants now.
Browse Anosmia studies →17 of the 59 studies in Anosmia with a site in United States are open now. Recruiting first, the newest first:
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 18–65 · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 18–80
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
Jeffrey Motter · Sites in United States
Ages 55–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Anosmia studies recruiting now, 14 (45%) set no upper age limit and 9 (29%) stop at 75 or younger; 3 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 16 · Phase 3 2 · Phase 4 3
First in 2004; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 28 is below the median of 60 across 114 interventional studies indexed under Anosmia.
Median enrollment 51 across the 43 interventional studies, 90 across the 16 observational. Of the 35 that completed or were terminated, 15 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 59 have an industry lead sponsor. The 10 most frequent:
Medical University of South Carolina is the lead sponsor of 875 studies on the registry; 165 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.
Medical University of South Carolina has 3 studies filed under Anosmia — fewer than ten, so there is no comparison to draw.
6 of the studies in Anosmia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04714892National Institute on Alcohol Abuse and Alcoholism (NIAAA)Mechanisms Underlying Individual Variations of Taste and Smell in Obesity | 2026-12-30 |
| NCT05881239Massachusetts General HospitalDigital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD | 2026-12-30 |
| NCT07681973The Cleveland ClinicCognitive and Immunologic Profiles of Patients With Olfactory Dysfunction After Smell Training | 2026-12-31 |
| NCT06733636Johns Hopkins UniversityScents of Progress: Leveraging a Novel Device for Olfactory Training in Older Adults | 2026-12-31 |
| NCT07546617Dartmouth-Hitchcock Medical CenterIn Vivo Imaging of the Olfactory Epithelium Using Confocal Laser Endomicroscopy | 2027-04-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 59 studies in Anosmia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates the causal effects of low-intensity transcranial focused ultrasound (tFUS) on odor valence perception and odor-elicited avoidance behaviors in healthy adults. Participants undergo sham and active tFUS targeting the amygdala (AMYG) and ventral striatal olfactory tubercle (VSOT) in a within-subject, randomized, sham-controlled crossover design. Outcomes include subjective odor ratings and objective neurophysiological and behavioral indices of odor valence processing. This research is exploratory and mechanistic in nature and is not intended to evaluate clinical safety or therapeutic efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active tFUS of the bilateral Amygdala randomized at one of the three stimulation visits
Device: transcranial focused ultrasound (tFUS)
Active tFUS of the bilateral VSOT randomized at one of the three stimulation visits
Device: transcranial focused ultrasound (tFUS)
Sham tFUS randomized at one of three stimulation visits
Device: transcranial focused ultrasound (tFUS)
non-invasive brain stimulation using tFUS
Odor Valence Rating
Participant rating of odor pleasantness on a 0-100 mm visual analog scale (e.g., unpleasant → pleasant)
Time frame: from the baseline visit until the third follow-up visit (about 1 month)
Late Positive Potential
Mean EEG amplitude (400-800 ms) at centro-parietal sites to olfactory-visual stimuli
Time frame: from the baseline visit until the third follow-up visit (about 1 month)
Sniff Volume
Total nasal airflow (in mL) per odor trial, measured via nasal cannula or spirometer
Time frame: from the baseline visit until the third follow-up visit (about 1 month)
Corrugator Supercilii EMG Activity
Mean EMG amplitude from facial muscle sensitive to negative affect and aversion
Time frame: from the baseline visit until the third follow-up visit (about 1 month)
Odor Intensity Rating
Participant rating of odor intensity on a 0-100 mm visual analog scale (e.g., not at all → extremely)
Time frame: from the baseline visit until the third follow-up visit (about 1 month)
Odor Avoidance Rating
Participant rating of their desire to avoid the odor on a 0-100 mm visual analog scale (e.g., "not at all" → "extreme")
Time frame: from the baseline visit until the third follow-up visit (about 1 month)
Sniff Rate
Breaths per min or per trial window in response to odor exposure
Time frame: from the baseline visit until the third follow-up visit (about 1 month)
Plan to share: Yes — Results (raw data and summarized) will be shared. A final de-identified data set will be made available for retrieval and analysis through OpenNeuro.org. All study protocols, including detailed descriptions of the study structure, data formats, and analytical methods, will be made available to ensure transparency and reproducibility. Associated documentation, including data dictionaries, codebooks, and analysis scripts, will be provided to enable others to replicate our methodology and build upon our findings. Data will be made available after publication of the findings.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data will be made available after publication of the findings. Data will be retained long enough to support the reproducibility of our published findings, the re-use by others, and as long as it is of value to the research community and/or public.
Access criteria: Data will be identifiable through a search engine for the title and other key words including the Modality: EEG, Task: odor-enhanced visual processing, Diagnosis: healthy controls, and Study Type: crossover. Additionally, we will provide the Openneuro Accession Number in any study communication.
Started Oct 2026 (actual). Primary completion is estimated for Apr 2028, 18 months after the start.
Of 50 non-industry interventional studies with no phase under Anosmia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 18 months is below that.
Counting every sponsor, half of 50 studies reached it within 28 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of South Carolina →